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1. Introduction 
Neuromuscular disease is a very broad term that encompasses many diseases and aliments 
that either directly, via intrinsic muscle pathology, or indirectly, via nerve pathology, impair 
the functioning of the muscles. Neuromuscular diseases affect the muscles and/or their 
nervous control and lead to problems with movement. Many are genetic; sometimes, an 
immune system disorder can cause them. As they have no cure, the aim of clinical treatment 
is to improve symptoms, increase mobility and lengthen life. Some of them affect the 
anterior horn cell, and are classified as acquired (e.g. poliomyelitis) and hereditary (e.g. 
spinal muscular atrophy) diseases. SMA is a genetic disease that attacks nerve cells, called 
motor neurons, in the spinal cord. As a consequence of the lost of the neurons, muscles 
weakness becomes to be evident, affecting walking, crawling, breathing, swallowing and 
head and neck control. Neuropathies affect the peripheral nerve and are divided into 
demyelinating (e.g. leucodystrophies) and axonal (e.g. porphyria) diseases. Charcot-Marie-
Tooth (CMT) is the most frequent hereditary form among the neuropathies and it’s 
characterized by a wide range of symptoms so that CMT-1a is classified as demyelinating 
and CMT-2 as axonal (Marchesi & Pareyson, 2010). Defects in neuromuscular junctions 
cause infantile and non-infantile Botulism and Myasthenia Gravis (MG). MG is a antibody-
mediated autoimmune disorder of the neuromuscular junction (NMJ) (Drachman, 1994; 
Meriggioli & Sanders, 2009). In most cases, it is caused by pathogenic autoantibodies 
directed towards the skeletal muscle acetylcholine receptor (AChR) (Patrick & Lindstrom, 
1973) while in others, non-AChR components of the postsynaptic muscle endplate, such as 
the muscle-specific receptor tyrosine kinase (MUSK), might serve as targets for the 
autoimmune attack (Hoch et al., 2001). Although the precise origin of the autoimmune 
response in MG is not known, genetic predisposition and abnormalities of the thymus gland 
such as hyperplasia and neoplasia could have an important role in the onset of the disease  
(Berrih et al., 1984; Roxanis et al., 2001).  
Several diseases affect muscles: they are classified as acquired (e.g. dermatomyositis and 
polymyositis) and hereditary (e.g. myotonic disorders and myopaties) forms. Among the 
myopaties, muscular dystrophies are characterized by the primary wasting of skeletal 
muscle, caused by mutations in the proteins that form the link between the cytoskeleton and 
the basal lamina (Cossu & Sampaolesi, 2007). Mutations in the dystrophin gene cause severe 
form of hereditary muscular diseases; the most common are Duchenne Muscular Dystrophy 
(DMD) and Becker Muscular Dystrophy (BMD). DMD patients suffer for complete lack of 
dystrophin that causes progressive degeneration, muscle wasting and death into the 
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second/third decade of life. Beside, BMD patients show a very mild phenotype, often 
asymptomatic primarily due to the expression of shorter dystrophin mRNA transcripts that 
maintain the coding reading frame. DMD patients’ muscles show absence of dystrophin and 
presence of endomysial fibrosis, small fibers rounded and muscle fiber 
degeneration/regeneration. Untreated, boys with DMD become progressively weak during 
their childhood and stop ambulation at a mean age of 9 years, later with corticosteroid 
treatment (12/13 yrs). Proximal weakness affects symmetrically the lower (such as 
quadriceps and gluteus) before the upper extremities, with progression to the point of 
wheelchair dependence. Eventually distal lower and then upper limb weakness occurs. 
Weakness of neck flexors is often present at the beginning, and most patients with DMD 
have never been able to jump. Wrist and hand muscles are involved later, allowing the 
patients to keep their autonomy in transfers using a joystick to guide their wheelchair. 
Musculoskeletal contractures (ankle, knees and hips) and learning difficulties can 
complicate the clinical expression of the disease. Besides this weakness distribution in the 
same patient, a deep variability among patients does exist. They could express a mild 
phenotype, between Becker and Duchenne dystrophy, or a really severe form, with the loss 
of deambulation at 7-8 years. Confinement to a wheelchair is followed by the development 
of scoliosis, respiratory failure and cardiomyopathy. In 90% of people death is directly 
related to chronic respiratory insufficiency (Rideau et al., 1983). The identification and 
characterization of dystrophin gene led to the development of potential treatments for this 
disorder (Bertoni, 2008). Even if only corticosteroids were proven to be effective on DMD 
patient (Hyser and Mendell, 1988), different therapeutic approaches were attempted, as 
described in detail below (see section 7). 
2. Treatment for neuromuscular diseases: gene and cell therapy  
The identification and characterization of the genes whose mutations caused the most 
common neuromuscular diseases led to the development of potential treatments for those 
disorders. Gene therapy for neuromuscular disorders embraced several concepts, including 
replacing and repairing a defective gene or modifying or enhancing cellular performance, 
using gene that is not directly related to the underlying defect (Shavlakadze et al., 2004). As 
an example, the finding that DMD pathology was caused by mutations in the dystrophin 
gene allowed the rising of different therapeutic approaches including growth-modulating 
agents that increase muscle regeneration and delay muscle fibrosis (Tinsley et al., 1998), 
powerful antisense oligonucleotides with exon-skipping capacity (McClorey et al., 2006), 
anti-inflammatory or second-messenger signal-modulating agents that affect immune 
responses (Biggar et al., 2006), agents designed to suppress stop codon mutations (Hamed, 
2006). Viral and non-viral vectors were used to deliver the full-length - or restricted versions 
- of the dystrophin gene into stem cells; alternatively, specific antisense oligonucleotides 
were designed to mask the putative splicing sites of exons in the mutated region of the 
primary RNA transcript whose removal would re-establish a correct reading frame. In 
parallel, the biology of stem cells and their role in regeneration were the subject of intensive 
and extensive research in many laboratories around the world because of the promise of 
stem cells as therapeutic agents to regenerate tissues damaged by disease or injury (Fuchs 
and Segre, 2000; Weissman, 2000). This research constituted a significant part of the rapidly 
developing field of regenerative biology and medicine, and the combination of gene and cell 
therapy arose as one of the most suitable possibility to treat degenerative disorders. Several 
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works were published in which stem cell were genetically modified by ex vivo introduction 
of corrective genes and then transplanted in donor dystrophic animal models.  
Stem cells received much attention because of their potential use in cell-based therapies for 
human disease such as leukaemia (Owonikoko et al., 2007), Parkinson’s disease (Singh et al., 
2007), and neuromuscular disorders (Endo, 2007; Nowak and Davies, 2004). The main 
advantage of stem cells rather than the other cells of the body is that they can replenish their 
numbers for long periods through cell division and, they can produce a progeny that can 
differentiate into multiple cell lineages with specific functions (Bertoni, 2008). The candidate 
stem cell had to be easy to extract, maintaining the capacity of myogenic conversion when 
transplanted into the host muscle and also the survival and the subsequent migration from 
the site of injection to the compromise muscles of the body (Price et al., 2007). With the 
advent of more sensitive markers, stem cell populations suitable for clinical experiments 
were found to derive from multiple region of the body at various stage of development. 
Numerous studies showed that the regenerative capacity of stem cells resided in the 
environmental microniche and its regulation. This way, it could be important to better 
elucidate the molecular composition – cytokines, growth factors, cell adhesion molecules 
and extracellular matrix molecules - and interactions of the different microniches that 
regulate stem cell development (Stocum, 2001).  
Several groups published different works concerning adult stem cells such as muscle-
derived stem cells (Qu-Petersen et al., 2002), mesoangioblasts (Cossu and Bianco, 2003),  
blood- (Gavina et al., 2006) and muscle (Benchaouir et al., 2007)-derived CD133+ stem cells. 
Although some of them are able to migrate through the vasculature (Benchaouir et al., 2007; 
Galvez et al., 2006; Gavina et al., 2006) and efforts were done to increase their migratory 
ability (Lafreniere et al., 2006; Torrente et al., 2003a), poor results were obtained.  
Embryonic and adult stem cells differ significantly in regard to their differentiation potential 
and in vitro expansion capability. While adult stem cells constitute a reservoir for tissue 
regeneration throughout the adult life, they are tissue-specific and possess limited capacity 
to be expanded ex vivo. Embryonic Stem (ES) cells are derived from the inner cell mass of 
blastocyst embryos and, by definition, are capable of unlimited in vitro self-renewal and 
have the ability to differentiate into any cell type of the body (Darabi et al., 2008b). ES cells, 
together with recently identified iPS cells, are now broadly and extensively studied for their 
applications in clinical studies. 
3 Embryonic Stem Cells (ESCs) 
Embryonic stem cells are pluripotent cells derived from the early embryo that are 
characterized by the ability to proliferate over prolonged periods of culture remaining 
undifferentiated and maintaining a stable karyotype (Amit and Itskovitz-Eldor, 2002; 
Carpenter et al., 2003; Hoffman and Carpenter, 2005).  They are capable of differentiating 
into cells present in all 3 embryonic germ layers, namely ectoderm, mesoderm, and 
endoderm, and are characterized by self-renewal, immortality, and pluripotency (Strulovici 
et al., 2007). 
3.1 Methods for ESCs isolation 
hESCs are derived by microsurgical removal of cells from the inner cell mass of a blastocyst 
stage embryo (Fig. 1). The ES cells can be also obtained from single blastomeres. This 
technique creates ES cells from a single blastomere directly removed from the embryo 
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bypassing the ethical issue of embryo destruction (Klimanskaya et al., 2006). Although 
maintaining the viability of the embryo, it has to be determined whether embryonic stem 
cell lines derived from a single blastomere that does not compromise the embryo can be 
considered for clinical studies. Cell Nuclear Transfer (SCNT): Nuclear transfer, also referred 
to as nuclear cloning, denotes the introduction of a nucleus from an adult donor cell into an 
enucleated oocyte to generate a cloned embryo (Wilmut et al., 2002). 
 
 
Fig. 1. ESCs differentiation. Differentiation potentiality of human embryonic stem cell lines. 
Human embryonic stem cell pluripotency is evaluated by the ability of the cells to 
differentiate into different cell types. 
3.1.1 ES cells from single blastomeres 
This technique creates ES cells from a single blastomere directly removed from the embryo 
bypassing the ethical issue of embryo destruction (Klimanskaya et al., 2006). Although 
maintaining the viability of the embryo, it has to be determined whether embryonic stem 
cell lines derived from a single blastomere that does not compromise the embryo can be 
considered for clinical studies.  
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3.1.2 Cell Nuclear Transfer (SCNT) 
Nuclear transfer, also referred to as nuclear cloning, denotes the introduction of a nucleus 
from an adult donor cell into an enucleated oocyte to generate a cloned embryo (Wilmut et 
al., 2002). The first application of this technique was in 1996 the creation of Dolly the sheep 
(Campbell et al., 1996). Transferred to the uterus of a female recipient, this embryo has the 
potential to grow into a clone of the adult donor cell, a process termed “reproductive 
cloning.” When explanted in culture, this embryo can give rise to embryonic stem cells that 
have the potential to become any or almost any type of cell present in the adult body. This 
process is also called “nuclear transplantation therapy” or “therapeutic cloning” because 
embryonic stem cells derived by nuclear transfer are genetically identical to the donor and 
thus potentially useful for therapeutic applications. It might substantially improve the 
treatment of neurodegenerative diseases, blood disorders, or diabetes, whose therapies are 
currently limited by the availability or immunocompatibility of tissue transplants 
(Hochedlinger and Jaenisch, 2003). Unfortunately, reproductive cloning is a largely 
inefficient and error-prone process that results in the failure of most clones during 
development due both to activation of inadequate pathways of early embryonic 
development (Solter, 2000) and suppression of pathway of differentiation (Rideout et al., 
2001). In contrast, reprogramming errors do not appear to interfere with therapeutic cloning, 
because the process appears to select for functional cells. Recent advances in the field of 
nuclear cloning showed that  most clones die early in gestation while cloned animals share 
abnormalities regardless of the type of donor cell or the species used, correlating with 
aberrant gene expression (Hochedlinger and Jaenisch, 2003).  Although experiments in 
animals showed that by SCNT it is possible to obtain primate ES cells (Byrne et al., 2007) and 
nuclear cloning combined with gene and cell therapy represents a valid strategy for treating 
genetic disorders (Rideout et al., 2002), the low efficiency of the technique, the difficulties in 
obtaining human eggs and the arising ethical problems are significant challenges to the 
widespread use of SCNT for the production of hESC. 
3.2 Characterization of ESCs 
Human embryonic stem cells (hESCs) were first derived from the inner cell mass (ICM) of 
the blastocyst stage (100–200 cells) of embryos generated by in vitro fertilization (Thomson et 
al., 1998), but methods have been developed to derive hESCs from the late morula stage (30–
40 cells) (Strelchenko et al., 2004), from arrested embryos (16–24 cells incapable of further 
development) (Zhang et al., 2006) and single blastomeres isolated from 8-cell embryos 
(Klimanskaya et al., 2006). Because hESCs have the potential to differentiate into normal 
tissues of all types, the ability to derive and maintain hESCs in culture gave rise to the 
possibility of having an unlimited supply of normal differentiated cells to engineer diseased 
tissues to regain normal function (Moon et al., 2006; Skottman et al., 2006).  
Nowadays, several studies demonstrating hESC differentiation into specific cell lineages use 
feeder layers of heterologous cells to maintain hESCs in culture and to signal the hESCs to 
differentiate into specific cell types (Conrad et al., 2008; Takahashi and Yamanaka, 2006). 
After transplantation into the recipient, the hESCs and their progeny could be exogenously 
controlled if they differentiated into malignant cells or if they otherwise grew and/or 
functioned in an unwanted lineage; if hESCs are to be useful in generating normal tissues 
for the treatment of human disease, the tissues to be transplanted must be compatible with 
the host such that the cells derived from the hESCs will not be recognized as “foreign” and 
rejected as would any transplanted tissue from an unrelated donor.  
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The first human stem cell line bank was opened in 2004 in the United Kingdom 
(http://www.ukstemcellbank.org.uk/). The National Institutes of Health registry 
(http://stemcells.nih.gov/research/registry/) has also archived a number of hESC lines 
and established criteria for demonstration of the pluripotency of these lines. Cells should be 
able to give rise to any cell lineage of the body and thus to form a teratoma (a tumour 
containing tissues from the 3 primary germ layers) after injection in an immune-suppressed 
animal and should be capable of unlimited self-renewal. A number of scientific/medical 
issues need to be addressed before stem cells can be considered safe for clinical applications.  
In fact for hESCs to be useful for therapy, technologies must be developed to provide them 
with the specific signals required to differentiate in a controlled lineage, to regulate and/or 
shut down the growth of hESCs and their progeny once they have been transferred to the 
recipient. Pluripotency is evidenced by the ability to form teratomas when transplanted in 
immunodeficient mice, the concern exists that these cells could form malignant tumours in 
their new host. One strategy for dealing with this problem is to select pure populations of 
more committed cells for transfer. Demonstrating genetic and epigenetic stability will 
therefore be important before these cells are used clinically. Moreover attention has to be 
focused on circumventing the host rejection of transplanted, non-autologous hESC-derived 
cells (Strulovici et al., 2007).  
Therefore, karyotypic abnormalities have been described in several hESC lines, although 
changes might be at least partially dependent on culture techniques (Mitalipova et al., 2005). 
In additional to biologic issues directly affecting the stem cell product, it is fundamental that 
controlled, standardized practices and procedures be followed to maintain the integrity, 
uniformity, of the human stem cell preparations. Because of stem cells are maintained and 
expanded in vitro before transplantation, culture conditions compatible with human 
administration must be used. Feeder cells and sera of animal origin have to be reduced and 
ideally avoided to reduce the potential risk of contamination by xenogeneic protein.  
Consequently, life-long immunosuppressive therapy, which can lead to infections and 
organ-based toxic side effects, such as nephropathy, might be required to prevent graft 
rejection (Brignier and Gewirtz, 2010). 
3.2.1 Expression markers 
Cell origins are often defined by one or more cell surface and or intracellular epitopes 
unique to that particular cell type. Stage-specific embryonic antigen (SSEA) markers are 
used to distinguish early stages of cell development, denoting pluripotency. These markers 
are globo-series glycolipids and are recognised by monoclonal antibodies. The SSEA-4 
epitope is the globo-series glycolipid GL7. It has been demonstrated that GL7 can react with 
antibodies to both SSEA-3 and SSEA-4 (Kannagi et al., 1983a; Kannagi et al., 1983b). Human 
ES cells will express SSEA-3 and -4 during pluripotency and only SSEA-1 upon 
differentiation (Andrews et al., 1996; Reubinoff et al., 2001; Thomson et al., 1998; Thomson 
and Marshall, 1998). The TRA-1-60 epitope adheres to a particular epitope of the 
proteoglycan and is sialidase sensitive, whereas antibody TRA-1-81 reacts with another 
unknown epitope of the same core proteoglycan molecule. Nanog is a NK-2-type 
homeodomain gene thought to encode a transcription factor that is critically involved in the 
self-renewal of stem cells. Thus, it may possibly act to repress genes necessary for 
differentiation and activate those involved in self-renewal. Lin and colleagues (Lin et al., 
2005) demonstrated that the tumour suppressor p53 binds to the promoter of Nanog. 
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Therefore, p53 can stimulate p53-dependent cell-cycle arrest and apoptosis when genetic 
integrity is not preserved. Oct-4, a POU-domain transcription factor, is highly expressed in ES 
cells (Niwa, 2001; Reubinoff et al., 2001; Thomson et al., 1998) and has been shown to be 
essential for maintaining pluripotency (Niwa, 2001). It has been reported that Oct-4 transcripts 
are nearly exclusively found in pluripotent cells in vivo and within culture. Oct-4 down-
regulation is observed in differentiating cells (Rosner et al., 1990). Not only is Oct-4 necessary 
for the maintenance of pluripotency, but its expression level governs three cell fates once 
differentiation occurs (Hay et al., 2004; Niwa et al., 2000). Several candidate genes have been 
reported as targets of Oct-4 based on stem cell expression patterns and immunoprecipitation, 
but few have been conclusively verified. Target genes of Oct4 include Rex-1, Lefty-1, 
PDGFalfaR and Utf-1, and those cooperating  with Oct4 include Sox2. In the ongoing search 
for the identification of pluripotent markers, Xu and colleagues have reported that the catalytic 
component of telomerase, telomerase reverse transcriptase or hTERT, is expressed in 
undifferentiated cells and down-regulated upon differentiation (Xu et al., 2001).  
3.3 Potentialities of ESCs 
ES-derived progenitors possess excellent self-renewal and regenerative potential, but the 
research on these cells is at the beginning. Recently, Jaenisch and collaborators published 
that the adult cells contain unipotent and multipotent stem cells such as haematopoietic 
stem cells even if totipotent and pluripotent cells are restricted to the early embryo (Jaenisch 
and Young, 2008). Although the decrease in developmental potential, the nuclei of most of 
adult cells maintain nuclear plasticity to reset to an embryonic state. It’s possible to enhance 
this process by exposing the oocyte to specific factors through nuclear transfer or the cells to 
pluripotent cell-specific factors by driving over-expression of defined transcription factors. 
However before the clinical applications of these cells, it’s needed to optimize the 
engraftment of hESCs and the development of a protocol to obtain similar populations of 
muscle precursors from human ES cells. ESCs are derived rather easily, and they can grow 
indefinitely in culture. Second, embryonic stem cells can be manipulated genetically by 
homologous recombination to correct a genetic defect (Rideout et al., 2001). Recently, Jiang 
and collaborators demonstrated pluripotency of mesenchymal stem cells derived from adult 
marrow, differentiating into cells of all three germ layers both in vitro and in vivo after 
being injected into blastocysts (Jiang et al., 2002). Unfortunately, they did not assess the 
ability of these cells in correcting a disease phenotype into both human or mouse animal 
models. Embryonic stem cells can become any type of cell through the use of specific culture 
conditions or genetic manipulation. To avoid the ethical and practical limitations of 
therapeutic cloning mentioned above, it would be useful to reprogram somatic cells directly 
into embryonic stem cells without the use of oocytes. For this reason, it’s necessary to deeply 
understand the role of several molecular factors in establishing and maintaining 
pluripotency, such as Oct-4 (Niwa et al., 2002). Oct-4 null embryos cannot form a 
pluripotent inner cell mass, consequently their development is arrested. To circumvent the 
need for human oocytes, it could be possible to modify the expression of Oct-4 and its 
related genes in somatic cells to reprogram their nuclei to an embryonic state.  
3.4 Drawbacks to clinic use of ESCs  
3.4.1 Host response to grafted tissue 
It is probable that ESCs will suffer from the same acute and chronic rejection problems that 
accompany other grafts and it is likely that this question will not be answered until these 
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cells are implanted into humans for the first time. Three methods have been proposed to 
avoid this problem. The first requires the use of somatic cell nuclear transfer (SCNT) 
techniques, as used to clone animals, to personalize ESCs. The nucleus of a somatic cell from 
the individual to be treated would be transferred into an enucleated donor oocyte, which 
would then be used to derive a blastocyst and subsequently isolate ESCs lines that would be 
genetically identical to the patient (Yang et al., 2007). In this case, any cell generated from 
the personalized ESC line should not be rejected. However, despite the claims of the South 
Korean Dr Hwang Woo-suk in 2005 that have subsequently been shown to be fraudulent, 
SCNT has not been successfully performed in human oocytes. It appears that the process is 
more complicated in humans than in animals where this technology has been used 
successfully in many species. The second method makes use of the capacity of ESCs to 
differentiate into multiple tissues and would involve replacing the recipients immune 
system with haematopoietic cells generated from the same ESC line as that used for tissue 
replacement. This technique has been used in solid organ transplants where patients have 
previously received bone marrow transplantation, and these patients did not require 
immune suppression (Helg et al., 1994). The third method used genetic manipulation to 
engineer ESCs in which MHC molecules or other immune effectors have been deleted 
(Hyslop et al., 2005). All these methods are under development. In addition to the immune 
response to the cells themselves, animal products are used to isolate ESCs in every methods, 
and it cause expression of animal proteins on the surface of the ES cells. This will also 
induce an immune response and a large amount of work is currently going into deriving 
and maintaining ESCs in total absence of these animal products and also undertaking these 
processes to the good manufacturing practice (GMP) standards required for clinical use. It is 
in the development of GMP protocols for the derivation and manipulation of ES cells.  
3.4.2 Cell proliferation and differentiation 
In addition to the problems connected with immune interactions, there are other important 
problems in providing a suitable number of cells for transplantation. The first problem is 
related to have the very large numbers of cells required for tissue replacement without 
tumour formation. As previously discussed, ES cells can form teratomas and therefore all 
undifferentiated cells will need to be removed from a graft. It is possible to circumvent this 
problem genetically modifying the cells by a suicide gene system. The expression of the 
suicide gene could be driven by the promoter of a gene such as Oct4 that is only expressed 
in undifferentiated cells; this technology has been used in gene therapy systems. Activation 
of the suicide gene by drug treatment of cell cultures would give rise to the death of the 
undifferentiated cells not affecting differentiating cells. Other methods include the 
expression of a genetic label such as the green fluorescent protein or a marker that enables 
cell sorting by FACS (Strulovici et al., 2007). In this case, cells could be selected using FACS 
for the surface markers expressed either excluding undifferentiated cells or positively 
selecting for the required differentiated cell type. Even if contaminating undifferentiated 
cells are removed, remain the problem due to the necessity to have a good number of 
mature cells able to form a robust graft and also maintaining the cells where they have to 
perform their therapeutically action. Differentiation protocols are being studying to generate 
very large number of cells (Joannides et al., 2007) and scaffolds able to keep the cells in place 
(Ferreira et al., 2007). Another aspect of tissue replacement that cannot be ignored is that few 
tissues are formed from a single uniform cell type. In order to regenerate a functional organ, 
it will be necessary to develop other structures such as vasculature and lymphatic drainage 
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systems as well as complex mixed cell populations (Caspi et al., 2007). These problems 
present a major challenge to tissue culture technology not only for ESCs but also for adult 
stem cells, and the development of new systems will be important in order to utilize ES cells 
to their maximum potential.  
3.4.3 Ethical implications to clinical use of ESCs 
The use of hESCs in medical research has focused much attention from many sectors of the 
public. Religious, historical, cultural, medical, and other points of view have contributed to a 
very vigorous and wide-ranging discourse over the use of these materials (Leist et al., 2008). 
Some consider research with hESCs to be inherently immoral because these individual’s 
believe that life begins with fertilization of the ovum, and the destruction of an embryo with 
the potential to develop into a viable human being is thought like an infanticide. For this 
reason, the American federal government severely restricted access and use of hESCs in 2001. 
These restrictions have now been largely overturned by the Obama administration. In contrast, 
proponents of this line of research insist that the potential benefits to human from this research 
mitigate such concerns. They also argue that hESCs are made from unwanted fertilized ovum 
that would likely be destroyed in any event. Stem cells created by means of nuclear transfer 
share the same ethical concerns. Furthermore, because these cells have the potential to 
generate a complete embryo, they also raise the even more highly charged possibility of 
cloning human beings, so-called reproductive cloning (Brignier and Gewirtz, 2010). Many 
organizations and countries have already banned reproductive cloning of human beings. 
Because this procedure can be used to generate stem cells for therapeutic purposes, in 
countries where this type of cloning is legal, such as Australia and the United Kingdom, the 
created embryos must be destroyed within 14 days. A human nucleus is transferred into an 
animal’s oocyte, creating a hybrid embryo that must be destroyed within 2 weeks and cannot 
be implanted. Clearly, creation of such tissues raises even more complex issues. Finally, the 
issue of financial compensation for embryo and gamete donors is also controversial, with 
guidelines for this problem being proposed by the International Society of Stem Cell Research 
(http://www.isscr.org/guidelines /index.htm). Everyone involved in the debate want very 
much to avoid the development of an underground black market in spare embryos ((Brignier 
and Gewirtz, 2010).  
3.4.4 Clinical applications of ESCs 
Among the important potential applications of gene therapy to hESCs is the correction of 
genetic diseases. Although many hereditary disorders can be targeted by gene therapy 
vectors alone, the combination of gene therapy and stem cell therapy may have added 
utility, where cells differentiated from hESCs would act as factories to produce therapeutic 
proteins or where a high proportion of corrected cells could be developed. In the case of 
circulating proteins (e.g., factor IX, factor VIII, von Willebrand factor, α1-antitrypsin), it may 
be possible to establish tissue reservoirs distant from the normal site of the secreted product 
(Mountford, 2008). The cells differentiated from hESCs can be delivered to a site accessible 
and receptive to transplantation, even if that tissue is not the normal site of production of 
the protein of interest. When the product is not secreted, the hESCs with their regulated 
genetic characteristics must be differentiated to the correct cell type (e.g., the cystic fibrosis 
transmembrane conductance regulator for cystic fibrosis or dystrophin for muscular 
dystrophy). Such proteins can exert their influence only at the appropriate site, and there is 
no known mechanism by which cells expressing the protein remote from the affected tissue 
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could have a therapeutic effect. Additional drawbacks are to be solved in order to obtain the 
successful therapeutic application of gene-modified hESCs including whether the hESC 
themselves, or the expressed product, will be toxic or immunogenic in the recipient. If the 
recipient of the cells, never exposed to the protein before, as in deletion or nonsense 
mutants, can be showed an immune reaction against the protein, limiting the effectiveness 
of the therapy (Mountford, 2008). 
To develop hESC-based therapies, it is obvious that strategies capable of mitigating risks 
related to the therapeutic use of hESCs should be pursued the development of the therapies. 
These strategies might include several non–mutually exclusive  mechanism for ablating all 
genetically modified cells while sparing most endogenous cells. The introduction of a step in 
the development of the therapy at which a single genetically modified cell would be 
isolated, expanded, and characterized with respect to the location of the mutation would 
allow an analysis of the relative risk of the insertion site. Similar limiting dilution cloning 
strategies are now routinely performed during the original isolation of a stem cell line to 
ensure that only one karyotype is represented (Mountford, 2008). Progress in understanding 
how insertional mutagenesis can lead to uncontrolled growth of stem cells is an essential 
prerequisite for this analysis and is currently an active area of research. Genetic modification 
can be used to enhance our ability to conduct such an isolation step by adding a convenient 
ligand for cell isolation. Genetic modification is also potentially useful for solving the 
problem of uncontrolled cell growth. Incorporating the genes for an ablation strategy at the 
same time as the genes for the therapeutic strategy would give the best chance of ensuring 
that the safety mechanism will be present when and if needed. Initial applications of 
genetically modified hESCs are likely to occur where the risk/benefit ratio tilts in favour of 
benefit, as in fatal disorders for which there is no therapy. The risks of the hESC therapies 
will have to be understood and probably reduced to maintain an appropriate risk/benefit 
ratio before these technologies can be applied to diseases that are inherently less dangerous 
to the patient. Gene therapy should prove to be valuable in reducing the risks associated 
with making hESC therapy a reality (Mountford, 2008).  
In particular, the ability to generate cells with in vivo muscle regenerative potential in 
culture and systemically transfer them to recipients is an important step towards the 
therapeutic application of ES cell-derived cells. Unfortunately, it’s not still provided a 
reproducible method to generate ES-derived myogenic progenitors for skeletal muscle 
regeneration. An ES cell–based therapy would have many advantages: it could allow the 
transplantation of a more primitive cell with greater replicative potential and patient-
specific ES cells could be induced from adult somatic cells. Moreover, the derivation of an 
ES cell–derived myogenic population with proliferative and regenerative potential has not 
been accomplished. Only two papers described some evidences for engraftment on 
transplantation of an ES cell–derived population but they were limited to qualitative 
detection of donor derived cells in recipient muscle (Bhagavati and Xu, 2005; Kamochi et al., 
2006). The Pax3 ES cell–derived population exhibited good potential for skeletal muscle 
regeneration but several studies concerning their capacity of replenish satellite cells-niche 
are in progress (Darabi et al., 2008a). On the other hand there is enough optimism about the 
ESC-based therapies because of it may offer reliable and cost-effective therapeutic substitute 
for treatment of neuromuscular disorders as DMD or BMD. Moreover there are critical 
issues that need attention in case of ESC-based approaches. No enough knowledge there are 
about genetic and epigenetic stability of hESC lines over longer time periods and it’s not 
negligible the possible uncontrolled cell proliferation and reprogramming of ESCs in vitro. 
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The injection of these cells could probably generate an immune rejection needed an 
immunosuppressive therapy. Optimization of a generic differentiation protocol and its 
empirical testing with  a better understanding of the molecular processes governing ESC 
differentiation can guarantee the clinical use of these cells. In conclusion the success of the 
clinical application of adult or embryonic stem cells will be employed to a large-scale 
production of desired cell type with appropriate functionality, an optimal number of cells 
for transplant, a modification of less invasive delivery systems and a technique to label cells 
for transplant and subsequent tracking of cell fate. 
4. Induced Pluripotent Stem Cells (iPS)  
The major impediment to ES based therapies in humans involves the moral and ethical 
problems linked to the blastocyst destruction and oocyte donation necessary to generate 
patient-specific pluripotent stem cell lines. These limitations have encouraged researchers to 
understand the mechanisms regulating pluripotency and to experimentally determine its 
gene expression program. Recent works describe the derivation of ES-like iPS cells from 
adult mouse and human cells (Nakagawa et al., 2008; Takahashi et al., 2007; Yu et al., 2009) 
by introducing specific sets of genes encoding transcription factors expressed in 
undifferentiated ES cells to reprogram the adult cells. Although initial studies indicating 
these cells to share characteristics of ‘‘true’’ ES cells, more detailed work is needed to 
determine how closely they resemble ES cells. Like ESCs, iPS cells can differentiate into all 
adult cell types. Researchers now have the ability to create tissue-based models of human 
disease based on cells derived from individual patients. This technology has the potential to 
herald a new era of patient-specific, cell-based medicine; however, given the oncogenic 
potential of undifferentiated iPS cells due to the unsafe reintroduction of these genes 
(Takahashi and Yamanaka, 2006), the safety of these cells has to be tested accurately before 
attempting any therapies. It has been demonstrated that continuous over-expression of 
transcription factors, especially the c-myc oncogene, may be associated with tumorigenesis 
(Takahashi et al., 2007). Even if it was demonstrated that the promoters of these viral vectors 
can be silenced by endogenous gene expression during reprogramming, chimeric mice 
derived from iPS cells were showed to be more prone to tumour formation. Following 
ameliorations in iPS technology, Nakagawa and co-workers generated pluripotent stem cells 
without c-myc over-expression both from mouse and human fibroblasts, with lower 
efficiency (Nakagawa et al., 2008). In addition, chimeric mice created from these non-myc 
iPS cells do not form tumours at an elevated rate. Recently, Chuang et al. proposed the use 
of baculoviral systems as a new gene delivery vector for stem cell engineering, and in 
particular for transgenic expression in human ESCs (Chuang et al., 2007). These vectors can 
be used for large segments, more than 30 kb, that do not fit into adenoviral or lentiviral 
vectors and could limit the risk derived from the great immunogenicity of adenoviral 
vectors.  
4.1 Methods for reprogramming human fibroblasts into iPS cells  
4.1.1 Production of iPS cells using viral integration 
In 2006, Yamanaka et al. identified four transcription factors—Klf4, Sox2, Oct4, and c-Myc 
able to transform mouse fibroblasts in pluripotent clones through retroviral transduction. 
The clones were selected for their ability to reactivate the non essential Oct4 downstream 
target gene, Fbx15 (Takahashi and Yamanaka, 2006). This first-generation of 
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Fig. 2 Generation of iPS cells. Reprogramming of adult stem cells in iPS cells mediated by 
Oct-4, Klf4, Sox2 and c-Myc give raise to ES like cells with embryonic potential. 
iPS cells exhibited partial demethylation and reactivation of the canonical pluripotency 
governing genes Oct4 and Nanog. In 2007, fully pluripotent iPS cells were generated by 
increasing the stringency of the selection strategy and selecting for reactivation of the 
pluripotency regulators Oct4 and Nanog themselves (Maherali et al., 2007; Okita et al., 2007; 
Wernig et al., 2007). These new second-generation iPS cells had fully demethylated Oct4 and 
Nanog promoters. These cells could not form viable mice by tetraploid complementation; an 
assay in which ES or iPS cells are injected into tetraploid blastocysts, resulting in embryos 
derived entirely from the injected cells, while extraembryonic tissues are derived from the 
host blastocyst. It is controversial if this failure is due to effects of the randomly integrated 
retroviral vectors used for reprogramming or represents a more fundamental defect in the 
developmental potency of iPS cells. Pluripotent iPS cells could be identified on the basis of 
their morphology, eliminating the need for genetically modified reporter genes and 
permitting the isolation of iPS cells derived from human fibroblasts (Park et al., 2008; 
Takahashi et al., 2007; Yu et al., 2009). After the work of Yamanaka, Yu et al generated  iPS 
cells starting from a combination of Oct4, Sox2, Nanog, and LIN28. The finding that direct 
epigenetic reprogramming with different combinations of transcription factors can be 
applied to human cells represents the breaking of a species barrier that SCNT has yet to 
overcome. The therapeutic value of iPS cells is the presence of proviral integrations 
harboring known oncogenes, particularly c-Myc, as well as Oct4 and Klf4. c-Myc was 
dispensable for iPS generation from fibroblast target cells (although iPS formation occurred 
with reduced efficiency), and chimeric mice derived from three-factor iPS cells (Oct4, Sox2, 
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and Klf4) did not exhibit tumour formation while the cells derived from the first four-factors 
showed tumorigenic characteristics (Nakagawa et al., 2008; Wernig et al., 2007). Despite the 
non essential role of c-Myc in the reprogramming process, the potential for insertional 
mutagenesis and the oncogenic properties of the other reprogramming factors has 
prompted several groups to undertake direct epigenetic reprogramming approaches using 
either nonviral methods, or retrospectively eliminate proviral integrations after iPS cell 
generation.  
4.1.2 Production of iPS cells  without viral integration 
Different reasons have drive the researchers to evolve strategies for lentivirus-free iPS cell 
generation. First, the introduction of foreign DNA able to integrate in random positions in 
the genome represent a risk for cell physiology giving rise to an insertional mutagenesis. 
The foreign DNA could destroy reading frames of genes or influences gene regulation. 
Moreover silencing of lentiviral transgenes is incomplete in iPS cells leading to reactivation 
of lentiviral vectors (Wernig et al., 2007). In fact basal expression of lentiviral 
reprogramming factors is found even in fully reprogrammed cells (Hotta and Ellis, 2008; 
Pfannkuche et al.). Pfannkuche et al. demonstrated that in murine iPS cultures, there was 
different expression of viral Oct4 by three orders of magnitude between spontaneously 
differentiating iPS and stable subclones of the same origin (Pfannkuche et al.). From several 
studies, it is known that altered levels of pluripotency factors influence the fate of 
pluripotent cells. Overexpression of Oct4 seems to direct ES cells towards an endodermal 
fate (Niwa et al., 2000; Pesce and Scholer, 2001). More strikingly, elevated levels of Sox2 can 
alter the whole network of pluripotency factors and abolish maintenance of pluripotency 
(Kopp et al., 2008; Rizzino, 2009). The best strategy to eliminate reprogramming factors or to 
prevent integration of foreign transgenes for generation of iPS cells for therapeutic issues 
could be to employ techniques that are able to reprogram somatic cells without the use of 
any type of DNA. One possibility to achieve this aim is the use of cell-permeable 
transcription factors. The application of cell permeable proteins for direct reprogramming 
has been shown with human newborn fibroblasts, but, again, the efficiency of 
reprogramming appears low (Kim et al., 2009a). Kim and co-workers includes incubation 
with the cell permeable factors for 42 days with six passage steps during incubation. Even if 
the efficiency appears low, this study demonstrated for the first time that cell-permeable 
proteins can reprogram somatic cells. However, the long incubation time of 6 weeks in the 
presence of recombinant reprogramming factors in culture media, could be difficult. The 
application of cell-permeable reprogramming factors is a very promising approach that 
certainly justifies further investigation to achieve efficient, less time consuming 
reprogramming of cells from adult donors. Recent results suggest that a substantial amount 
of cell permeable reprogramming factors is enclosed in endosomes after cell uptake and 
might therefore be unavailable for reprogramming (Pan et al.). Another possibility to 
perform reprogramming is the introduction of RNA that can be transfected into cells. 
Transport of synthetic mRNAs to the nucleus is not necessary and, therefore, the 
transfection efficiency to deliver mRNA to the cytoplasm might be high. The stability of 
RNA limit the reprogramming efficiency and to obtain the right amount of protein 
translated it will be necessary several rounds of transfection to achieve reprogramming. A 
further strategy to induce pluripotency without the generation of stably transfected cells is 
the use of non integrating viruses. Adenoviral vectors were designed to express 
reprogramming factors and transport the coding sequence transiently into the target cells. 
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Application of the adenoviral approach on fetal human fibroblasts resulted in the generation 
of stable human iPS cells without viral integration. The human iPS cells form teratomas in 
vivo, which is the most stringent assay applicable to test their pluripotency (Zhou and Freed, 
2009). Adenoviral vectors could enhance the production of virus- free iPS cells but the use of 
viruses that are DNA-based still bears a residual risk of integration into the host genome. 
This might be overcome with an RNA-based virus to generate safe iPS cells without 
application of DNA based vectors.  
Another possible approach is the use of a single plasmid containing Oct4, Klf4, c-myc and 
Sox2 stably transfected into somatic cells for reprogramming. The plasmid expressed a 
single mRNA that codes for all four reprogramming factors and the red-fluorescent protein 
(RFP) in order to discriminate the transfected cells (Kaji et al., 2009). Different studies are 
also focused on the application of transposon-based systems. The application of the piggy-
BAC transposon allows delivery of reprogramming factors into cells of different organisms 
and stable integration of the reprogramming genes into the genome by action of the 
transposase enzyme transiently transfected in a plasmid, and it is able to catalyse the 
integration of the reprogramming factors (Woltjen et al., 2009). The whole cassette is flanked 
by inverted terminal repeats, which mediate insertion into the genome by the host-factor 
independent activity of a transposase. The principal advantage of the system is not only the 
higher efficiency to deliver reprogramming factors but also the possibility to remove the 
transgene. Expression of reprogramming factors from the transposon was controlled by a 
doxicyclin inducible promoter, in order to guarantee a temporal control of transcription 
factors.  
4.1.3 Generation of iPS cells with less than Yamanaka’s four factors  
Researchers are looking for solutions to reduce the number of factors needed for 
reprogramming. One of the reasons is to reprogram the cells using chemical compounds in 
order to standardize the procedure conditions, to control the response of each compound 
and to regulate the reprogramming factor expression. Another reason is that reduction of 
reprogramming factors to perhaps a single transgene could guarantee the understanding of 
mechanisms underlying reprogramming. Between the four factors used by Yamanaka, c-
myc has been thought to have the highest oncogenic potential. The three other factors were 
not associated with tumorigenesis. The role of Klf4 in carcinogenesis is ambiguous. It can act 
as a tumour suppressor gene, especially in gastrointestinal tumours, or as oncogene, in the 
development of breast carcinoma where it is involved in the early phase of malignant 
transformation (Rowland and Peeper, 2006). The first reduction to three factors Oct4, Sox2 
and Klf4 induced pluripotency in mouse and human fibroblasts (Nakagawa et al., 2008; 
Wernig et al., 2007) and other somatic cell types (Park et al., 2008). Moreover the generation 
of iPS cells was possible combinating Oct4, Sox2 and c-myc in the absence of Klf4. It was 
concluded that Oct4 and Sox2 in combination with either c-myc or Klf4 were sufficient (Park 
et al., 2008). Other researchers studied the use of another set of factors including Sox2, Oct4 
and the nuclear receptor Essrb, which could replace Klf4 for reprogramming (Feng et al., 
2009). However, the estimated reprogramming efficiency was ten times higher than in the 
original 4-factor approach in fibroblasts. Finally, reprogramming using only Oct4 in the 
absence of any other factor became possible in neural stem cells derived from adult mice 
(Kim et al., 2009b) and humans (Kim et al., 2009a). Another strategy is the substitution of 
single reprogramming factors by small molecules. For example c-myc or Klf4, could be 
substitute with valproic acid (VPA), thus making reprogramming of human fibroblasts 
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possible only by retroviral transduction of Oct4 and Sox2 (Huangfu et al., 2008), with a 200-
fold reduction of reprogramming efficiency compared to Oct4, Sox2 and Klf4 in combination 
with VPA. VPA acts as histone deacetylase inhibitor (Huangfu et al., 2008). Other authors 
utilized high-throughput assays to identify chemical factors which can substitute 
reprogramming genes. For example, Klf4 could be chemically substituted by the application 
of kenpaullone (Lyssiotis et al., 2009), and two other small molecules (BIX-01294 and 
Bayk8644) could enable reprogramming of embryonic fibroblasts with only Oct4 and Klf4.  
4.1.4 Enhancement of iPS production 
Due to the low efficiency of iPS production, different factors have been investigated in order 
to improve this procedure. Simultaneous transduction of c-myc, Oct4, Sox, Klf4, with Nanog 
and Lin28 increases efficiency dramatically (Liao et al., 2008). Other studies have shown that 
expression of p53 siRNA and UTF1 dramatically increases iPS colonies (Zhao et al., 2008). 
While p53 siRNA remarkably increases the number of iPS colonies, UTF1, a pluripotent 
marker and necessary for the maintenance of pluripotency in mES cells (Gaspar-Maia et al., 
2009). By affecting different pathways, these two factors together can synergize iPS 
generation (Zhao et al., 2008). Other pathways which have an impact on iPS cells formation 
include the TGFβ and the MEK-ERK pathway. The role of these pathways in cell survival 
has made them beneficial in reprogramming studies. Chemical inhibitors of the MEK 
pathway apparently inhibit the growth of non-iPS cells while increasing the growth rate in 
reprogrammed iPS cells. Suppressing MEK and TGFβ pathways concurrently with chemical 
compounds increases iPS amounts. This study showed that combined suppression of both 
pathways resulted in extensive amounts of iPS generation in comparison to individual 
inhibition of each pathway (Lin et al., 2009). Repression of the Ink4/Arf locus which is a 
regulator of the p53 p21 pathway has a positive effect on reprogramming. Different 
pluripotency genes are controlled by the expression of different micro RNAs expressed in 
the cell. For example, let-7 is one of the miRNAs which targets the 3’UTR and ORF’s of 
several pluripotency expressed genes including c-myc, Oct4, Sox2 and Nanog. Suppressing 
let-7 by antisense inhibitors improves iPS generation several fold in mouse embryonic 
fibroblasts (MEFs) (Melton et al. , 2010). Reduced oxygen levels favour the growth of 
haematopoietic stem cells and maintain ES cells in a pluripotent state. Induction of 
pluripotency in hypoxic conditions increases the number of iPS colonies and vitamin C 
elevates iPS reprogramming efficiency (Esteban et al. , 2010). The increase in iPS formation is 
not due to its antioxidant activity but vitamin C inhibits p53, thus facilitating the induction 
of iPS cells (Shi et al. , 2010). Vitamin C extends the life span of both iPS and MEF cells 
pointing at roles for vitamin C in anti-ageing. Composition of the iPS culture medium also 
defines the efficiency of iPS formation. The use of transcription factors together with 
different chemical agents can enhance iPS induction. This can result in the derivation of 
more pluripotent cells in a shorter time, making its application more convenient for clinical 
purposes in a not too far future.  
4.2 Clinical applications of  iPS 
Following the success of haematopoietic stem cell therapy in the treatment of 
haematological diseases, the potential application of cell based therapy has been extended to 
the treatment of other human diseases. In particular, different types of adult stem cells, 
including bone marrow, peripheral haematopoietic, and mesenchymal stem cells (MSC) 
have been evaluated in the treatment of different diseases ( Charwat et al., 2010; Siu et al., 
www.intechopen.com
 
Stem Cells in Clinic and Research 
 
452 
2010). ESCs have been explored for tissue regeneration because of their ability to 
differentiate into various therapeutic relevant cell types in vitro (Murry and Keller, 2008). 
Despite this, there is limited progress in the use of ESCs for tissue regeneration in humans 
due to various technical, social and religious issues (Kiskinis and Eggan). The generation 
of patient-specific iPS cells has the advantage of avoiding many of the ethical concerns 
associated with the use of embryonic or foetal material, and have no risk of immune 
rejection. Currently, several therapeutic relevant cell types, including motor neuron 
(Dimos et al., 2008), hepatocytes (Song et al., 2009), pancreatic insulin producing cells 
(Zhang et al., 2006), haematopoietic cells (Hanna et al., 2007), retinal cells (Carr et al., 
2009), cardiomyocytes (Zwi et al., 2009) and MSCs (Lian et al., 2010), have been 
successfully derived from human iPS cells, and some of them have been tested to treat 
diseases in animal models. The use of iPS cells has thus been proposed as diagnostic and 
therapeutic tools for different haematological disorders (Ye et al., 2009). Nelson et al. 
(Nelson et al., 2009) reported the use of iPS cells for myocardial repair in animal models of 
acute myocardial infarction. There are several major challenges to overcome before iPS 
cell technology is applied in clinical practice. Now, current iPS cells are not “clinical 
grade”. Genome-integrating viral vectors used for reprogramming are known oncogenes, 
particularly c-Myc, Oct4 and Klf4, such that iPS cells thus generated are unlikely to be safe 
for clinical application. Nonetheless recent technological advances, including 
reprogramming without viral integration such as plasmids or direct reprogramming 
protein delivery assays can solve this problem (Kiskinis and  Eggan, 2010; Saha and 
Jaenisch, 2009). Despite the challenges in the therapeutic use of iPS cells, preclinical 
studies have provided the proof-of-concept that patient-specific iPS cells can provide an 
unlimited cell source to produce massive therapeutic cell types, such as cardiomyocytes 
and MSCs, and can be prepared in an “off the- shelf ” format for cell transplantation.  
Given the many potential risks of applying autologous iPS cell treatment to human 
subjects, iPS cell therapies may encounter strict regulatory restrictions. For instance, it 
took Geron Corporation more than 6 years to receive approval from the Food and Drug 
Administration (FDA) for its human ES cell-derived neuronal cell (GRNOPC1) therapies 
in terms of cell product safety and reliability. Recently, a second company has presented 
an investigational new drug for a phase I/II trial using human ES cell-derived retinal 
pigment epithelial (RPE) cells to treat patients with Stargardt’s Macular Dystrophy 
(SMD), one of the most common causes of juvenile blindness. The sponsoring company, 
Advanced Cell Technology (ACT), has performed years of testing to show that 
differentiated RPE cells can improve the visual performance of rats without adverse 
effects (e.g., teratomas) in hundreds of treated animals. Another issue that may hinder the 
clinical translation of iPS cell therapies is the economic feasibility of producing 
individualized iPS cell therapeutic products. The viability of a business model for patient-
specific iPS treatment is still unknown. It may well be the case that few if any 
pharmaceutical companies will be able to produce cost-effective individualized iPS cell 
products tailored for a single patient at a time. To be commercially feasible, these cells 
will need to be made in standardized, large-scale production, and the individual needs or 
profiles of patients will need to be easily assessed to allow matching and wide 
distribution (Sun et al., 2010). Several groups have also begun the generation of patient-
specific human iPS cell lines. Park et al. generated a library of patient-derived iPS lines 
from numerous disorders including Huntington’s disease, juvenile diabetes mellitus, 
Down syndrome, muscular dystrophy, and several others (Park et al., 2008). Of particular 
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interest are iPS cells derived  from neurodegenerative diseases (Dimos et al., 2008; Ebert et 
al., 2009). These iPS lines can be differentiated in vitro into the affected neuronal cell type, 
generating for the first time a model for idiopathic neurodegenerative disorders which 
can be screened in culture for the onset, cell autonomy, and contribution of environmental 
factors to the phenotype. Ultimately, if human neurodegenerative phenotypes can be 
recapitulated in iPS cell-derived culture models, these cells could be screened using 
chemical libraries to identify molecules that can arrest or even reverse the progression of 
these disorders.  
5. Similarities and differences between ES and iPS cells 
The comparison of iPS and ES cells revealed that these cells are very similar. The 
differentiation capacity of iPS cells seems to resemble that of ES cells; iPS derived somatic 
cells are comparable to those derived from ES cells. Several studies describe the derivation 
of a variety of cell types from murine and human iPS cells, among them cardiomyocytes, 
smooth muscle cells, hepatic cells and neurons with similar differentiation behaviour of iPS 
and ES cells. The transcriptome of iPS and ES cells was analyzed by Gene chip analysis; the 
results showed that these cells are very similar but they are not identical. Chin and co-
workers compared the expression pattern of different human ES and iPS cells; they analysed 
histone modifications and the expression of non-coding miRNAs in both type of cells and 
they constructed a fingerprint of iPS cells that distinguishes them from ES pluripotent cells 
(Pfannkuche et al., 2010). The comparison of the transcriptome of early and late passage iPS 
cells with ES cells revealed two datasets of differentially regulated genes. They identified a 
subset of 318 genes differentially expressed between human ES and iPS cells at any stage. 
The genes that are higher expressed in iPS cells were also found higher expressed in 
fibroblasts than in ES cells. The same conclusion is valid for genes that were expressed at a 
lower level in iPS than ES cells are usually also lower expressed in fibroblasts than ES cells. 
Together, these findings point at an imperfect reprogramming of a small set of genes. It is 
not known if there are implications of iPS fingerprint for the physiology of these cells. It is 
important determine the genes that are differentially regulated and that could influence the 
cellular physiology. It is likely that some of these gene functions are redundant with others 
that are not affected by incomplete reprogramming and, therefore, do not influence cell 
physiology (Pfannkuche et al., 2010).  
Beside genes that constitute a potential iPS cell fingerprint, there are varying gene sets that 
are differentially expressed in individual iPS cell lines. It will be interesting to see if 
properties of the ancestral cell types are transmitted to the iPS cell line generated. In this 
regard, partial reprogramming plays a role and one fascinating aspect to address is if partial 
reprogramming alters the differentiation capacity of a cell in a way that it potentially 
influences the fate decision of the partially reprogrammed iPS cells. The differences between 
iPS and ES cells could be an assays to measure the quality of iPS cells. Although it has been 
shown that the overall gene expression of iPS cells differs from normal ES cells, this 
comparison has never been made between cells from the same individual. Usually iPS cells 
are compared with those ES cells either derived from another species or from a different 
individual; raising concerns about whether these are informative approaches. It is clear, 
therefore, that iPS cells derived from the trophoblast of an embryo compared with ES cells 
derived from the inner cell mass of the same embryo would give a more explicit view of 
how distinct or similar these cells really are (Pfannkuche et al., 2010).  
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6. Adult stem cells versus ESC&iPS 
Although ESCs and iPS cells are now the most studied cells for clinical applications in 
neuromuscular diseases, different stem cells isolated from adult tissues was extensively used – 
and are still used – unfortunately with poor results. For several years after they were 
discovered, the satellite cell were considered as the only cells responsible for the growth and 
maintenance of skeletal muscle. With the improvements of  cell-isolation technology, a number 
of markers were described to identify muscular and non-muscular subpopulations able to 
actively participate in myogenesis (Meregalli et al., 2010). In the skeletal muscle, adult multi-
lineage progenitor cell populations were showed to have myogenic potential, such as muscle-
derived stem cells (MDSCs) and muscle-derived CD133+ progenitors. Moreover, it was also 
shown that non-muscular resident stem cells could participate in myogenesis (Krause et al., 
2001; Mezey et al., 2000; Pittenger et al., 1999; Prockop, 1997). In particular, a subpopulation of 
CD133+ cells was isolated form the blood, playing an important role in myogenic 
development (Torrente et al., 2003b) while mesoangioblasts were identified in the dorsal aorta 
of avian and mammalian species (Cossu and Bianco, 2003).  
6.1 Satellite cells  
Satellite cells are small progenitor cells that lie between the basement membrane and 
sarcolemma of individual muscle fibers: normally they are quiescent, consequently they 
cannot differentiate nor undergo cell division. Oxidative stress and specific stimuli form the 
environment can activate them, so that they differentiate, proliferate as skeletal myoblasts 
and activate myogenic differentiation to form new myofibers. Recently, Montarras and 
colleagues were able to directly isolate a pure population of satellite cells from diaphragm 
muscle of a Pax3-GFP knock-in mouse (Montarras et al., 2005). After FACS and gene 
expression analysis, they purified a predominantly quiescent population of satellite cells 
expressing Pax3, CD34 and Pax7. These cells were firstly injected into dystrophic dogs and 
restored dystrophin expression 3 weeks post-transplantation.  Transplanted into irradiated 
dystrophic mice, they also formed a small amount of the satellite cell pool that expressed 
both Pax7 and Pax3 (Montarras et al., 2005). If compared with the results obtained after the 
injection of human cells isolated from adult muscle, these cells showed an incredibly 
efficient level of muscular regeneration (Morgan et al., 1996). Since they were doubtless 
highly myogenic, satellite cells were not considered in a clinical point of view, because it 
was difficult to isolate them and above all to proliferate and expand them to obtain the right 
number for transplantation experiments. Moreover, the growth of freshly isolated satellite 
cells in vitro significantly reduced their in vivo myogenic potential.  
6.2 Muscle-derived stem cells (MDSCs) 
Muscle-derived stem cells (MDSCs) are a recently-identified subpopulation of cells that 
resides within skeletal muscle and possess the ability to self renew and to differentiate into 
other mesodermal cell types (Sarig et al., 2006; Tamaki et al., 2007). Furthermore, it’s known 
that these cells are distinct from satellite cells (Asakura and Rudnicki, 2002; Qu-Petersen et 
al., 2002) and that, when appropriately stimulated, they could preserve their myogenic 
potential in vitro even after differentiation into other lineages (Negroni et al., 2006). In the 
last years, different works assessed the capacity of MDSCs to differentiate and regenerate 
skeletal muscle when transplanted into animal models. Sca-1+CD34+ stem cells were 
purified from the muscle tissues of newborn mice, showing multipotency in vitro. 
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Moreover, after intra-arterial injection, these cells were able to interact and firmly adhere to 
endothelium in mdx muscles microcirculation and then participated in muscle regeneration 
(Torrente et al., 2003a). Qu-Petersen and collaborators isolated a MDSCs population Sca-
1+/-CD34+/-c-kit-CD45- and demonstrated that they displayed a better transplantation 
efficiency than satellite cells (Qu-Petersen et al., 2002). MDSCs were also identified in 
human muscle, expressing in proliferation the CD133 antigen and also desmin and α-SMA 
when cultured in myogenic conditions (Miraglia et al., 1997). Moreover, among human 
MDSCs, it was identified  a subpopulation of progenitor stem cells with neurogenic 
properties (Alessandri et al., 2004). According to these evidences, MDSCs are suitable for 
clinical perspectives as they are easy to proliferate, migrate through the vasculature, and are 
multipotent, although it could be necessary to better investigate their physiological location 
(Deasy et al., 2005; Deasy et al., 2001).  
6.3 Mesoangioblasts  
Mesoangioblasts are multipotent progenitors of mesodermal tissues, physically associated 
with the embryonic dorsal aorta in avian and mammalian species, expressing Flk-1, stem 
cell antigen 1, CD34 and various leukocyte molecules (Cossu and Bianco, 2003; Tagliafico et 
al., 2004). It was shown that mesoangioblasts treated with a lentiviral vector expressing 
human microdystrophin were able to produce dystrophin-positive myofibers after injection 
in animal model of DMD and ameliorated muscle function and mobility (Cossu and 
Sampaolesi, 2007; Sampaolesi et al., 2006). Furthermore, to improve their efficiency of 
muscle repair, mesoangioblasts were treated to increase their migration to skeletal muscle 
and to reduce unspecific trapping in the capillary filters of the body, such as liver and lung 
(Galvez et al., 2006).  
6.4 CD133+ stem cells  
A role for CD133 as a marker of stem cells with the capacity to engraft and differentiate to 
form functional non-haematopoietic adult lineages and contribute to disease amelioration 
via tissue regeneration emerged in the last years. Human CD133+ cells, isolated from 
peripheral blood and manipulated in vitro to undergo myogenesis, were shown to 
ameliorate disease via a direct contribution to muscular regeneration when transplanted 
into dystrophic mice (Torrente et al., 2004). In particular, they restored dystrophin 
expression and eventually regenerate the murine satellite cells pool after intramuscular 
and intra-arterial delivery. Human CD133+ cells colonized the mouse muscle and formed 
hybrid regenerated fibers expressing human dystrophin. Moreover, they were detected in 
several vessels near areas of regeneration, where they expressed human ve-cadherin and 
CD31 (Torrente et al., 2004). A CD133+ stem cell subpopulation was also identified in 
normal and dystrophic muscles. They were positive for CD45 antigen, indicating their 
hematopoietic commitment while the expression of Pax-7, Myf-5, MyoD, m-cadherin, 
MRF-4, and myogenin after 24 days of culture in the proliferation medium and their 
ability to differentiate into multinucleated myotubes expressing MyHCs suggested a 
myogenic commitment (Torrente et al., 2007). According to these data, CD133+ stem cells 
were considered as a possible tool in the treatment of degenerating diseases. Stamm and 
collaborators showed that transplanted BM-derived CD133+ cells improved function of 
infracted myocardium probably as a result of the amelioration in blood vessel formation 
(Stamm et al., 2003) while Torrente and co-workers demonstrated that intramuscular 
transplantation of muscle-derived CD133+ cells in DMD patients was a safe procedure 
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and feasible. DMD patients showed an increased number of capillaries per muscle fiber 
and expressed a change in the ratio of slow-to-fast myosin myofibers (Torrente et al., 
2007). Human dystrophic blood- and muscle-derived CD133+ expressed an exon-skipped 
version of human dystrophin after transduction with a lentivirus carrying a construct 
designed to skip exon 51 and participated in vivo in muscle regeneration (Benchaouir et 
al., 2007). This combination of cell- and gene-based approaches via the ex vivo 
introduction of corrective genes into dystrophic CD133+ cells permitted – in a clinical 
point of view- the use of patient’s own cells: autologous transplantation would reduce the 
risk of implant rejection.  
7. Therapeutic potential of adult and embryonic stem cells 
Several questions remain to be answered before any of the previously described cell 
preparations can be moved into clinical trials even if there has been great advance in the 
generation of cell populations showed in vivo myogenic potential. Based on their unique 
characteristics and in vivo skeletal muscle regeneration potential, adult stem cell 
populations discussed in this review are excellent clinical candidates. As shown before, 
mesoangioblasts (Cossu and Bianco, 2003) and blood derived CD133+ (Gavina et al., 2006) 
have the ability to migrate through the vasculature, most do not. Potential future methods to 
increase the migratory ability of stem cell population include the identification of cell 
surface markers like adhesion molecules (Torrente et al., 2003b) and appropriate growth 
factors (Horsley et al., 2003; Torrente et al., 2003b). Mesoangioblasts serve as a paradigm for 
widespread distribution, and after treatment with growth factors are able to correct 
efficiently the dystrophic phenotype. For now the intra-arterial injection of mesoangioblasts 
represent a hope for patients suffering from various muscular dystrophies. Satellite cells 
was one of the first cell types used in cell-based therapy of muscular dystrophy. Expanded 
satellite cells or myoblasts were isolated from wild-type mice and intramuscularly injected 
in dystrophic mdx mice (Conway et al., 1997; Tremblay et al., 1998); unfortunately it was 
demonstrated that myoblast transplantation is an inefficient technique because of the low 
efficiency of the dystrophin production in muscle fibers of DMD patients and no functional 
or clinical improvement in the children (Peault et al., 2007). In possible future clinical trials, 
adult stem cells purified from patients suffering for neuromuscular disorders could be ex 
vivo engineered and re-injected in the initial donor intra-arterially. The intra-arterial 
injections of the patient’s own stem cells transduced allow the distribution of the cells to the 
whole body musculature so that it could be possible to take care of severe-affected patients 
that have reduced mass body, as in DMD and BDM pathology (Brignier and Gewirtz, 2010). 
One of the most important problem to solve for future clinical application is the 
amelioration in safety procedures of gene’s modifications. One of the most reliable methods 
for gene therapy, fully utilized in DMD clinical approaches, seems to be the exon skipping 
mediated by AONs or molecules like PTC124. Ongoing phase I/II studies try to assess the 
efficacy and the safety of intramuscular administered morpholino oligomer directed against 
exon 51 (AVI-4658 PMO). Morpholinos can interfere with mRNA splicing processes by 
preventing the formation of the snRNP complex or by interfering with the binding sites for 
other regulatory proteins (Vetrini et al., 2006). They mediate the exclusion of exons from the 
mature mRNA as AONs. PTC124 was shown to partially restore dystrophin production in 
animals with DMD due to a nonsense mutation. The main purpose of a phase II study 
completed on May 2007 was to understand whether PTC124 can safely increase functional 
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dystrophin protein in the muscles of patients with DMD due to a nonsense mutations. This 
study demonstrated the safety and the efficacy of the PTC124 treatment; now three ongoing 
phase 2a and 2b studies are started in DMD and BMD patients (www.clinicaltrials.gov). 
A decade of studies in human ESCs has yielded remarkable progress and understanding in 
stem cell biology. The technical challenge of creating patient-specific ESCs, the ethical issues 
arising from the foetal origin of human ESCs and the potential risk of immune rejection 
make broad clinical application of this cell type difficult. Recent advances in human iPS cell 
technology can potentially circumvent these disadvantages: iPS cells thus provide an 
invaluable resource of cell types for modelling diseases, drug or toxicology screening, and 
patient-specific cell therapy. Significant challenges remain to be overcome before the full 
potential of human iPS cell technology can be realised. The utilization and practical 
application of ESC in cell replacement therapy are still in a preliminary stage and need more 
investigation and clinical trials before they can be accepted as ideal for the treatment of 
neuromuscular diseases. Nevertheless, the daily increase in experimental findings is 
reinforcing the hope that ESC will be a versatile source of renewable cells for application in 
cell replacement therapy (Brignier & Gewirtz, 2010). Therefore, there is enough optimism 
among the scientists that ESC-based therapies may offer reliable and cost-effective 
therapeutic substitute for treatment of severe degenerative disorders in the near future. 
Major objection to hES cell research is focused one ethical reasons. The core reason for 
objection to hES cell research is that it destroys human blastocysts or embryos, which means 
it destroys human lives and eventually violates human dignity because of the blastosysts 
have the same moral value as that of human beings or at least that blastocysts have the 
potential to develop into human beings (Jung, 2009). Accordingly, research with hESCs is 
increasing exponentially worldwide, particularly in the United States, where important 
limitations on research with such cells were overturned in 2009. Furthermore, the US Food 
and Drug Administration trial using hESC-based therapy in patients with spinal cord injury 
is now on-going. Nonetheless, a number of substantive scientific and ethical issues remain 
to be resolved before hESCs can enter the therapeutic mainstream. In the meantime, recent 
breakthroughs in generating iPSCs would obviate the need to solve the most vexing of these 
problems. In fact, it seems reasonable to hope that in the next few years many of the 
enabling issues relevant to iPSCs will be solved, allowing the field of regenerative medicine 
to deliver on its vast potential promise. Although it is difficult to predict the ultimate utility 
of stem cell–based therapy at this time, it is not difficult to conclude that this is an extremely 
important area of scientific research. Open discussions between political bodies and the 
various interest groups in the scientific, medical, and religious communities need to take 
place to address the concerns of each and to provide an ultimate solution that is clearly in 
the interest of humanity.  
8. Conclusions 
European Medicines Agency (EMEA) issued the guideline to replace the Points to Consider 
on the Manufacture and Quality Control of Human Somatic Cell Therapy Medicinal 
Products (CPMP/BWP/41450/98). In general, when a cell-based medicinal product (CBMP) 
enters the clinical development phase, the same requirements as for other medicinal 
products apply. The clinical development plan should include pharmacodynamic studies, 
pharmacokinetic studies, mechanism of action studies, dose finding studies and randomised 
clinical trials in accordance to the Directive 2001/20/EC and to the existing general 
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guidances and specific guidances for the condition evaluated. It takes into account the 
current legislation and the heterogeneity of human cell-based products, including 
combination products. A risk analysis approach can be used by the applicants to justify the 
development and evaluation plans and can be a basis for the preparation of a risk 
management plan. Special problems might be associated with the clinical development of 
human cell-based medicinal products. Guidance is therefore provided on the conduct of 
pharmacodynamic/pharmacokinetic studies, dose finding and clinical efficacy and safety 
studies. The guideline describes the special consideration that should be given to 
pharmacovigilance aspects and the risk management plan for these products. The active 
substance of a CBMP is composed of the engineered (manipulated) cells and/or tissues. 
When the cells in the active substance are genetically modified, the “Note for Guidance on 
the quality, preclinical and clinical aspects of gene transfer medicinal products” should be 
followed, which gives details on the quality control, characterisation and preclinical testing 
of gene transfer vectors. Cell populations which are transformed should be assayed for 
appropriate and reproducible expression of the newly acquired characteristics. Special 
attention should be paid to the level and length of expression and quality of the gene 
product(s) produced by the cells. As far as applicable and practicable, the new 
characteristics of the cells should be quantified and controlled. During in vitro cell culture, 
consideration should be given to ensure acceptable growth and manipulation of the isolated 
cells. The processing steps should be properly designed to preserve the integrity and control 
the function of the cells and their manipulation should be documented in detail and closely 
monitored according to specific process controls. Moreover, the duration of cell culture and 
maximum number of cell passages should be clearly specified and validated. The relevant 
genotypic and phenotypic characteristics of the primary cell cultures, of the established cell 
lines and the derived cell clones should be defined and their stability with respect to culture 
longevity determined. Consistency/repeatability of the cell culture process should be 
demonstrated and the culture conditions including the media and the duration should be 
optimised with respect to the intended clinical function of the cells. If genetically modified 
cells are used in the product, any additional proteins expressed from the vector, such as 
antibiotic resistance factors, selection markers, should be analysed to determine their 
presence in the product. Microassay for gene expression profile, flow cytometry and other 
different techniques allowed these expression studies. CBMP might require administration 
through specific surgical procedures, method of administration or the presence of 
concomitant treatments to obtain the intended therapeutic effect. The biological effects of 
CBMP are highly dependent on the in vivo environment, and may be influenced by the 
replacement process or the immune reaction either from the patient or from the cell-based 
product. These requirements coming from the clinical development should be taken into 
account for the final use of these products. Their standardisation and optimisation should be 
an integral part of the clinical development studies. Ahead of these considerations it’s not 
still provided a reproducible method to isolate ESCs even if an ES cell–based therapy would 
have many advantages: it could allow the transplantation of a more primitive cell with 
greater replicative potential and patient-specific ES cells could be induced from adult 
somatic cells. The development of several ESC-based technologies, such as genetic 
manipulation tools and their potential applications, could accelerate the use of these cells 
into clinical therapy, even if ethical, logistics and economics concerns need attention in case 
of ESC-based techniques. There are several major challenges to overcome before iPS cell 
technology is applied in clinical practice. First, current iPS cells are not “clinical grade”. 
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Genome-integrating viral vectors used for reprogramming are known oncogenes, 
particularly c-Myc, Oct4 and Klf4, such that iPS cells thus generated are unlikely to be safe 
for clinical application. Nonetheless recent technological advances, including 
reprogramming without viral integration such as plasmids or direct reprogramming protein 
delivery assays could solve this problem (Kiskinis and Eggan, 2010; Saha and Jaenisch, 
2009). Despite the challenges in the therapeutic use of iPS cells, preclinical studies provided 
the proof-of-concept that patient-specific iPS cells can provide an unlimited cell source to 
produce massive therapeutic cell types, such as cardiomyocytes and MSCs, and can be 
prepared in an “off the- shelf ” format for cell transplantation.  However given the many 
potential risks of applying autologous iPS cell treatment to human subjects, iPS cell 
therapies may encounter strict regulatory restrictions. 
At now in our opinion the most promising results in the treatment of neuromuscular 
disorders were obtained using adult stem cells because of many questions are needed to be 
answer regarding the ES and iPS cells. According to the results described, the most 
promising possibility for the therapy of muscular dystrophies is a combination of different 
approaches to obtain the beneficial impact of multiple strategies combined into a single 
approach, such as cellular therapy associated with gene therapy or pharmacological 
treatments. One of the most used approach is called autologous transfer in which patient’s 
own cells are genetically corrected in vitro with lentiviral vectors and then re-implanted to 
allow the re-expression of functional dystrophin protein. The ‘exon skipping’ approach is an 
alternative strategy for gene therapy and it is done through AONs that hybridize with the 
donor and/or acceptor sites of the mutated exon, causing its exclusion from the intact 
transcript. On the other side, the allogenic transfer implies that the cells isolated from an 
individual with functional dystrophin will be injected into the patient, allowing problems 
due to immunorejections or administration of specific immunosuppressive drugs. Several 
problems arose quickly, such as the low efficiency with which stem cells enter muscle via 
vasculature, the potential to enhance proliferation of stem cells in culture, the time required 
in culture for autologous cells prior to implantation back into the patient, the longevity of 
the transplanted muscle nuclei in vivo, the development of tumours as a consequence of 
hazardous integration of the provirus. In conclusion the success of the clinical application of 
adult or embryonic stem cells will be employed to a large-scale production of desired cell 
type with appropriate functionality, an optimal number of cells for transplant, a 
modification of less invasive delivery systems and a techniques to label cells for transplant 
and subsequent tracking of cell fate. 
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studies can prove to be a breakthrough in preventing developmental disorders. Meanwhile, many researchers
conduct these studies to understand the molecular and cellular basis of cancer development. The fact that
cancer is one of the leading causes of death throughout the world, highlights the importance of these
researches in the fields of biology and medicine.
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